tetano
Editor, Senior Moderator
Diabetes Metab J
. 2021 Mar 5.
doi: 10.4093/dmj.2020.0206. Online ahead of print.
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee[SUP] 1 [/SUP], Jeongwoo Lee[SUP] 2 [/SUP], Hyewon Nam[SUP] 2 [/SUP], Dae-Sung Kyoung[SUP] 2 [/SUP], Dong Wook Shin[SUP] 3 [/SUP], Dae Jung Kim[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin-angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM).
Methods: As of May 2020, analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Insurance Review and Assessment Service (HIRA) database in Korea. Using this dataset, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade. Additionally, we validated the results using the National Health Insurance Service (NHIS) of Korea dataset.
Results: Totally, data of 67,850 subjects were accessible in the HIRA dataset. Of these, 5,080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 (95% confidence interval [CI], 0.135 to 0.971), and that for RAS blockade users was 0.599 (95% CI, 0.251 to 1.431). These findings were consistent with the analysis based on the NHIS data using 704 final subjects. The adjusted odds ratio for severe treatment among DPP-4i users was 0.303 (95% CI, 0.135 to 0.682), and that for RAS blockade users was 0.811 (95% CI, 0.391 to 1.682).
Conclusion: This study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19.
Keywords: Angiotensin-converting enzyme 2; COVID-19; COVID-19 drug treatment; Diabetes mellitus; Dipeptidyl peptidase 4.
. 2021 Mar 5.
doi: 10.4093/dmj.2020.0206. Online ahead of print.
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee[SUP] 1 [/SUP], Jeongwoo Lee[SUP] 2 [/SUP], Hyewon Nam[SUP] 2 [/SUP], Dae-Sung Kyoung[SUP] 2 [/SUP], Dong Wook Shin[SUP] 3 [/SUP], Dae Jung Kim[SUP] 4 [/SUP]
Affiliations
- PMID: 33752274
- DOI: 10.4093/dmj.2020.0206
Abstract
Background: Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin-angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM).
Methods: As of May 2020, analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Insurance Review and Assessment Service (HIRA) database in Korea. Using this dataset, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade. Additionally, we validated the results using the National Health Insurance Service (NHIS) of Korea dataset.
Results: Totally, data of 67,850 subjects were accessible in the HIRA dataset. Of these, 5,080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 (95% confidence interval [CI], 0.135 to 0.971), and that for RAS blockade users was 0.599 (95% CI, 0.251 to 1.431). These findings were consistent with the analysis based on the NHIS data using 704 final subjects. The adjusted odds ratio for severe treatment among DPP-4i users was 0.303 (95% CI, 0.135 to 0.682), and that for RAS blockade users was 0.811 (95% CI, 0.391 to 1.682).
Conclusion: This study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19.
Keywords: Angiotensin-converting enzyme 2; COVID-19; COVID-19 drug treatment; Diabetes mellitus; Dipeptidyl peptidase 4.